Skip to main content
Fig. 5 | Arthritis Research & Therapy

Fig. 5

From: Integrative analysis reveals CD38 as a therapeutic target for plasma cell-rich pre-disease and established rheumatoid arthritis and systemic lupus erythematosus

Fig. 5

Dose-dependent depletion by daratumumab of plasma cells and plasmablasts from peripheral blood mononuclear cell (PBMC) samples ex vivo. a Representative fluorescence-activated cell sorting (FACS) plot of combined plasma cells/plasmablasts. Shown is pre-gated on live singlet CD3CD56CD19low/midCD20 lymphocytes. From left to right, plot shows the representative plasma cell/plasmablast population at 1 μg/ml isotype control, 0.0003 μg/ml daratumumab, 0.01 μg/ml daratumumab and 1 μg/ml daratumumab (Dara), respectively. Number in the quadrant shows absolute number of CD27hiCD38hi plasma cells-plasmablasts in each condition at 72 h post-culture. b Quantification of plasma cell/plasmablast number at 72 h post-culture with isotype control or daratumumab at indicated concentrations. c Dose-response of plasma cell/plasmablast depletion by daratumumab in all donors with systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) and healthy donors combined. d Representative FACS plot of CD27IgD memory B cell, CD27+IgD class-switched memory B cell and CD27+IgD+ non-class-switched memory B cell at 72 h post-culture in the presence of daratumumab at each indicated concentration. Number in the quadrant shows absolute number of each memory B cell subset. e-g Slight increase in non-class-switched memory B cell (e), CD27+ class-switched memory B cell (f) and CD27 memory B cell (g) compared to isotype control at each indicated concentration. For each individual donor at each daratumumab concentration, triplicate wells were combined for quantification in a, b and d and then normalized to isotype control in c and e-g Data shown represent four healthy controls, five donors with SLE and four with RA

Back to article page